Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Clinical trial NCT06022757 · TERMINATED

Trial details

NCT number: NCT06022757
Sponsor: Evopoint Biosciences Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma Squamous Cell Carcinoma of Head and Neck Urothelial Carcinoma Prostate Cancer Small-cell Lung Cancer Non-small Cell Lung Cancer Cervical Cancer Other Solid Tumors

Start date: 2023-09-20
Primary completion: 2025-01-13
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.